What are the monitoring guidelines for a non‑cirrhotic patient with chronic hepatitis C and a baseline HCV RNA level of 3.2 million IU/mL who is initiating direct‑acting antiviral therapy?

Monitoring Guidelines for Non-Cirrhotic Chronic Hepatitis C Patient Declining Treatment

For a non-cirrhotic patient with chronic hepatitis C (HCV RNA 3.2 million IU/mL) who declines direct-acting antiviral therapy, implement surveillance every 6-12 months with hepatic function panel, complete blood count, and INR, plus ultrasound screening for hepatocellular carcinoma every 6 months if advanced fibrosis (F3) is present 1.

Disease Progression Monitoring

Since this patient is declining treatment, the focus shifts entirely to surveillance for disease progression and complications:

Laboratory Monitoring (Every 6-12 Months)

• Hepatic function panel (ALT, AST, bilirubin, alkaline phosphatase, albumin)
• Complete blood count (to detect thrombocytopenia suggesting portal hypertension)
• International normalized ratio (INR) (to assess synthetic liver function)
• Calculate MELD score if cirrhosis develops 1

Fibrosis Assessment

The critical question is whether this patient has advanced fibrosis (Metavir F3 or F4), which dramatically changes surveillance requirements:

• If F0-F2 (no advanced fibrosis): No additional surveillance beyond the laboratory monitoring above is required 1
• If F3 or F4 (advanced fibrosis/cirrhosis): Add HCC surveillance with ultrasound every 6 months 1

Determine fibrosis stage using transient elastography (FibroScan®), which is used by >90% of specialists and is the preferred non-invasive method 2. Serum biomarkers are used by <20% and are less reliable 2.

Hepatocellular Carcinoma Surveillance

If advanced fibrosis (F3) or cirrhosis (F4) is present, perform abdominal ultrasound every 6 months 1. This is critical because patients with advanced fibrosis remain at significant risk for HCC even without treatment.

Endoscopic Surveillance

If cirrhosis develops, perform endoscopic surveillance for esophageal varices 1. The frequency depends on initial findings and follows standard variceal screening protocols.

Ongoing Reassessment for Treatment

Periodically re-evaluate the patient for retreatment as new, more effective, or better-tolerated therapies become available 1. With the viral load of 3.2 million IU/mL, this patient would be an excellent candidate for 12-week sofosbuvir/ledipasvir therapy if they change their mind, as the baseline HCV RNA is below 6 million IU/mL 3.

Critical Pitfalls to Avoid

1. Do not assume non-cirrhotic status without objective testing: Clinical judgment alone (imaging, AST, platelet count) is acceptable, but transient elastography provides more reliable staging 4

2. Do not neglect HCC surveillance in F3 patients: Advanced fibrosis (F3) carries HCC risk similar to cirrhosis and requires the same 6-month ultrasound surveillance 1

3. Do not perform routine HCV RNA monitoring: Viral load monitoring is not indicated in untreated patients and does not change management 1

4. Do not order resistance-associated variant (RAV) testing: This is only indicated before treatment initiation in specific scenarios (genotype 1a with certain regimens), not for surveillance 1

Monitoring Intensity Based on Fibrosis Stage

The monitoring algorithm hinges entirely on fibrosis stage:

For F0-F2 (minimal to moderate fibrosis):

• Laboratory panel every 6-12 months
• No imaging surveillance
• Reassess for treatment willingness

For F3-F4 (advanced fibrosis/cirrhosis):

• Laboratory panel every 6-12 months
• Ultrasound every 6 months for HCC
• Endoscopy for varices (if cirrhotic)
• More aggressive counseling for treatment

The baseline viral load of 3.2 million IU/mL is clinically relevant for treatment planning (falls below the 6 million threshold for shortened 8-week therapy in some regimens) 3, 4, but does not affect surveillance strategy in an untreated patient.